Cargando…
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
Autores principales: | Fleming-Dutra, Katherine E., Ciesla, Allison Avrich, Roper, Lauren E., Smith, Zachary R., Miller, Joseph D., Accorsi, Emma K., Verani, Jennifer R., Shang, Nong, Derado, Gordana, Wiegand, Ryan E., Pilishvili, Tamara, Britton, Amadea, Link-Gelles, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949847/ https://www.ncbi.nlm.nih.gov/pubmed/36795625 http://dx.doi.org/10.15585/mmwr.mm7207a3 |
Ejemplares similares
-
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022) -
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness
in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron
BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent
Adults — Increasing Community Access to Testing Program, United States,
December 2022–January 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023) -
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022) -
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
por: Moulia, Danielle L., et al.
Publicado: (2023) -
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)